<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243851</url>
  </required_header>
  <id_info>
    <org_study_id>KNOG-1501</org_study_id>
    <nct_id>NCT03243851</nct_id>
  </id_info>
  <brief_title>Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma</brief_title>
  <acronym>METT</acronym>
  <official_title>Efficacy and Safety of Low Dose Temozolomide Plus Metformin as Combination Chemotherapy Compared With Low Dose Temozolomide Plus Placebo in Patient With Recurrent or Refractory Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong-Kil Hong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin
      as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with
      recurrent or refractory Glioblastoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or
      placebo for the patients with recurrent or refractory Glioblastoma.

      The dosage of the Metformin will follow the domestically permitted dose to minimize side
      effects.

      The patients will be allocated randomly to arm 1(experimental) and arm 2(placebo controlled)
      and administered the investigational products for up to 6 cycle. Each cycle consists of 4
      weeks.

      After 6 cycle(24 weeks), the patients will be checked progression and survival every 24 weeks
      up to 96 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1 : Low dose temozolomide+metformin Arm 2 : Low dose temozolomide+placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of progression-free survival obtained from progression-free survival curve</measure>
    <time_frame>24 weeks</time_frame>
    <description>Comparison of progression-free survival obtained from progression-free survival curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks thereafter every 24 weeks up to 96 weeks</time_frame>
    <description>Tumor Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control probability</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks thereafter every 24 weeks up to 96 weeks</time_frame>
    <description>Tumor control probability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month progression free survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>6 month progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month overall survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>6 month overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks</time_frame>
    <description>EORTC QLQ-C30 and EORTC QLQ-BN20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide :
1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
Metformin :
1st cycle (4 weeks)
1 week(1st~7th day) = 1,000mg/day
1 week(8th~14th day) = 1,500mg/day
2 weeks(15th ~28th day) = 2,000mg/day
2nd to 6th cycle (20 weeks) = 2,000mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Temozolomide :
1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
Placebo:
1st cycle (4 weeks)
1 week(1st~7th day) = 1,000mg/day
1 week(8th~14th day) = 1,500mg/day
2 weeks(15th~28th day) = 2,000mg/day
2nd to 6th cycle (20 weeks) = 2,000mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide+Metformin</intervention_name>
    <description>Low dose temozolomide+metformin for 24 weeks</description>
    <arm_group_label>Temozolomide+metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide+Placebo</intervention_name>
    <description>Low dose temozolomide+placebo for 24 weeks</description>
    <arm_group_label>Temozolomide+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Progressive or recurrent Glioblastoma conformed by histopathological or radiological
             diagnosis. Progressive or recurrent Glioblastoma during or after standard therapy
             (Temozolomide after Temozolomide and radiation therapy; Stupp regimen) after
             histopathological diagnosis of Glioblastoma Recurrence or progression is diagnosed
             according to histopathological diagnosis or revised RANO(Response Assessment in
             Neuro-Oncology) criteria c

          2. Karnofsky performance status(KPS) ≥ 60%

          3. Age ≥ 19 years old

          4. At least 4 weeks after operation or chemotherapy

          5. Normal in hematological finding, liver and kidney function

               -  Hematology ANC &gt; 1.500/mm³, Platelet &gt; 100,000/mm³, WBC &gt; 3×10^9/L, Hemoglobin &gt;
                  9g/dL

               -  Liver function Total Bilirubin level ≤ 1.5×ULN(in case of isolated
                  hyperbilirubinemia ≤2.5 x ULN) AST / ALT &lt; 2.5×ULN

               -  Renal function Serum creatinine ≤ 1.5mg/dL

          6. Be informed of the nature of the study and obtained a written informed consent

          7. A legal representative agrees to the trial when a subject is unable to communicate
             smoothly due to neurologic defect

          8. If a fertile woman who has been confirmed negative to a urine or blood pregnancy test
             within 28 days prior to the trial

        Exclusion Criteria:

          1. Pregnant or breast feeding

          2. Cancer history within 5 years excluding cancer in the skin cells and cervix

          3. Active infections within two weeks

          4. Leptomeningeal metastasis

          5. Patients diagnosed with diabetes

          6. Hypersensitive or intolerance to Metformin

          7. Patients who are currently taking Metformin, sulfonylureas, thiazolidinediones, and
             insulin, regardless of reason

          8. Other serious diseases or medical conditions that include :

               -  Patients who suffer from unstable heart disease despite treatment.

               -  Patients having a heart attack within 6 months prior to the start of trial

               -  Patients who suffer from severe nerve or psychosis that includes dementia or
                  strokes.

               -  Patients with an uncontrolled infection

               -  Patient with uncontrolled hypertension, congestive heart failure, unstable
                  angina, or incomplete arrhythmia

          9. Those who have participated in other clinical trials may not recover from the toxicity
             of the treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Kil Hong, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Kil Hong, MD., PhD.</last_name>
    <phone>+82-2-2258-2101</phone>
    <email>hongyk@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung Ho Yang, MD., PhD.</last_name>
    <phone>+82-31-249-8304</phone>
    <email>72ysh@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-Do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heon Yoo, MD., PhD.</last_name>
      <phone>+82-31-920-1249</phone>
      <email>heonyoo@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-Do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Jung Kim, MD., PhD.</last_name>
      <phone>+82-31-787-8210</phone>
      <email>cong1005@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Hyuk Kim, MD., PhD.</last_name>
      <phone>+82-31-219-3559</phone>
      <email>nsksh@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-Do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Jung, MD., PhD.</last_name>
      <phone>+82-2-379-8954</phone>
      <email>sjung@chonnam.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Sup Chung, MD., PhD.</last_name>
      <phone>+82-32-280-5876</phone>
      <email>dschung@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Min Kim, MD., PhD.</last_name>
      <phone>+82-2-2072-1672</phone>
      <email>gabriel9@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Hee Chang, MD., PhD.</last_name>
      <phone>+82-2-2228-2162</phone>
      <email>changjh@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Cho Koh, MD., PhD.</last_name>
      <phone>+82-2-2030-7622</phone>
      <email>kohyc@kuh.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Hoon Kim, MD., PhD.</last_name>
      <phone>+82-2-3010-3559</phone>
      <email>jhkim1@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do Hyun Nam, MD., PhD.</last_name>
      <phone>+82-2-3410-3497</phone>
      <email>nsnam@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Kil Hong, MD., PhD.</last_name>
      <phone>+82-2-2258-2101</phone>
      <email>hongyk@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hospital, Korea</name>
      <address>
        <city>Suwon-si</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Ho Yang, MD., PhD.</last_name>
      <phone>+82-31-249-8304</phone>
      <email>72ysh@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Yong-Kil Hong</investigator_full_name>
    <investigator_title>MD., PhD.</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

